Pglyrp3 cooperates with Snail1 to mediate anti-tumor immune response in breast cancer

Pglyrp3与Snail1合作介导乳腺癌的抗肿瘤免疫反应

• 批准号: 10215253
• 负责人: Mathew Sebastian
• 金额: $ 4.71万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-16 至 2022-05-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10215253
• 关键词: Address; Anti-Bacterial Agents; Autoimmunity; Breast; Breast Cancer Model; Breast cancer metastasis; CCL17 gene; CCL22 gene; Cancer Etiology; Cells; Cessation of life; Computer Analysis; Data; Data Set; Detection; Disease Progression; Epithelial; Evolution; Gene Expression Profiling; Genes; Genetic; Goals; Immune; Immune checkpoint inhibitor; Immune system; Immunity; Immunologic Surveillance; Immunotherapy; Individual; Interleukin-17; Intrinsic factor; Mammary Neoplasms; Mediating; Mesenchymal; Modeling; Molecular; Mus; Neoplasm Metastasis; Pathway interactions; Patients; Penetrance; Play; Population; Prevention; Proteins; Regulation; Regulator Genes; Regulatory T-Lymphocyte; Research; Resistance; Role; Shapes; Surveillance Program; Therapeutic; Tumor Escape; Tumor Immunity; Woman; Work; anti-PD1 antibodies; anti-PD1 therapy; anti-tumor immune response; base; cancer subtypes; cancer therapy; chemokine; cytokine; design; disorder risk; effector T cell; epithelial to mesenchymal transition; human model; immunogenic; immunoregulation; implantation; improved; innovation; knock-down; malignant breast neoplasm; mouse model; neoplastic cell; novel; peptidoglycan recognition protein; prevent; recruit; response; small hairpin RNA; synergism; targeted treatment; triple-negative invasive breast carcinoma; tumor; tumor growth; tumor microenvironment; tumor-immune system interactions; tumorigenesis

Project Summary/Abstract This application seeks to understand the mechanism of breast cancer’s relative resistance to immunotherapy, including immune checkpoint inhibitors, and to identify potential targets to overcome this resistance. Immune escape is a hallmark of disease progression and metastasis and a major impediment to designing efficacious anticancer therapies. Breast cancer is considered less immunogenic, and thus relatively resistant to immunotherapy such as immune checkpoint inhibitors (ICI), although there is evidence of only a modest response to ICIs in patients with triple negative breast cancer (TNBC) compared to other breast cancer subtypes. The exact mechanism for this relative resistance of breast cancer to ICIs remains unclear. However it is increasingly clear that recruiting inhibitory immune cells such as regulatory T cells (Treg) to the tumor microenvironment is an effective way tumors employ to suppress effective anti-tumor immunity and promote immune escape. In this proposal, we describe the application of a novel computational approach to identify and validate the underlying tumor cell-intrinsic molecular determinants of intratumoral Treg stability and immune escape. Our objective is to identify novel targets in breast cancer to prevent immune escape and to enhance breast cancer’s response to ICIs. To that end we have discovered a novel subnetwork regulated by Snail1, a master epithelial-to-mesenchymal transition (EMT) initiating factor, which is predicted to confer an immune surveillance program by suppressing the intratumoral Treg population. The central hypothesis of this proposal is that Snail1 negatively regulates Pglyrp3, a protein known for its Treg recruitment functions, therefore limiting the Treg population, enhancing anti-tumor immunity and response to ICIs. In Aim 1, we will determine the impact of the Snail1-Pglyrp3 interaction on intratumoral Treg stability using breast cancer models. Specifically, we will manipulate levels of Pglyrp3 in Snail1-positive or -negative backgrounds and determine how the intratumoral Treg population is impacted and whether additional factors are required for the Snail1-Pglyrp3 interaction to be functional. In Aim 2, we will determine whether targeting the Snail1-Pglyrp3 interaction is sufficient at enhancing response to immune checkpoint inhibitors and improving survival. This work is significant because it will demonstrate a novel network involved in switching from an immune-active to immune-suppressed tumor microenvironment that shapes tumor evolution. This work is innovative in that it will provide novel targets that can be pursued to prevent breast tumors from immune evasion and to sensitize them to ICIs.

项目摘要/摘要 这个应用程序试图了解乳腺癌对免疫治疗的相对抵抗机制， 包括免疫检查点抑制剂，并确定克服这种耐药性的潜在靶点。免疫 逃避是疾病进展和转移的标志，也是设计有效药物的主要障碍 抗癌疗法。乳腺癌被认为免疫原性较低，因此对 免疫治疗，如免疫检查点抑制剂(ICI)，尽管有证据表明只有适度的 与其他乳腺癌亚型相比，三阴性乳腺癌(TNBC)患者对ICIS的反应。 乳腺癌对ICIS的这种相对耐药的确切机制尚不清楚。然而，它是这样的 越来越清楚的是，招募抑制性免疫细胞，如调节性T细胞(Treg)到肿瘤 微环境是肿瘤抑制有效抗肿瘤免疫、促进免疫的有效途径 免疫逃逸。在这项提案中，我们描述了一种新的计算方法的应用，以识别和 验证瘤内Treg稳定性和免疫的潜在肿瘤细胞内在分子决定因素 逃走。我们的目标是在乳腺癌中识别新的靶点，以防止免疫逃逸和增强 乳腺癌对ICIS的反应。为此，我们发现了一个由Snail1调控的新子网络，一个 主要的上皮向间充质转化(EMT)启动因子，据预测可提供免疫 通过抑制肿瘤内Treg种群的监视计划。这项提议的中心假设是 Snail1负性调节Pglrp3，这是一种以Treg募集功能闻名的蛋白质，因此限制了 Treg群体，增强抗肿瘤免疫和对ICIS的反应。在目标1中，我们将确定 利用乳腺癌模型研究Snail1-Pglrp3相互作用对瘤内Treg稳定性的影响。具体来说，我们将 操纵Snail1阳性或阴性背景中Pglrp3的水平，并确定肿瘤内 Treg种群是否受到影响以及是否需要其他因素才能使Snail1-Pglrp3相互作用 功能齐全。在目标2中，我们将确定以Snail1-Pglrp3相互作用为目标是否足以增强 对免疫检查点抑制剂的反应和提高存活率。这项工作意义重大，因为它将 展示了一个新的网络，参与了从免疫活跃的肿瘤到免疫抑制的肿瘤的转换 塑造肿瘤进化的微环境。这项工作具有创新性，因为它将提供新的目标 可用于防止乳腺肿瘤的免疫逃逸，并使其对ICIS敏感。